IFM Therapeutics

Boston, United States · Founded 2015 · $82.5M raised

Employees
11–50
Founded
2015
Business Model
B2B
Total Funding
$82.5M
Last Round
$55.5M Series BDec 2019
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

IFM Therapeutics is a Boston, Massachusetts-based biopharmaceutical company dedicated to improving the lives of patients with cancer and inflammatory diseases by developing transformative medicines that target the innate immune system. Founded in October 2015 by Gary Glick and scientific co-founders from the University of Michigan and Germany, IFM pioneered drug discovery around key innate immune nodes including NLRP3 and STING. The original company (IFM Uno) was acquired by Bristol Myers Squibb in 2017 for $300M upfront; the autoimmune programs were spun out as IFM Therapeutics LLC, which subsequently launched IFM Tre (sold to Novartis in 2019 for $1.575B) and IFM Due (sold to Novartis in 2024 for $835M), demonstrating a serial value-creation model in innate immunology.

Summary

IFM Therapeutics is a Biotech company based in Boston, United States, founded in 2015. It has raised $82.5M in total across 2 rounds, most recently a $55.5M Series B round in Dec 2019. Investors include Abingworth Bioventures, Atlas Venture and Omega Funds.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2019
$55.5M

Sign up to see all 2 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

IFM Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/ifm-therapeutics"><img src="https://indexed.vc/api/badge/company/ifm-therapeutics" alt="IFM Therapeutics on Indexed.vc" width="260" height="76" /></a>